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Introduction: Pure invasive micropapillary carcinoma (IMPC) is a special type of breast carcinoma characterised by
clusters of cells presenting polarity abnormalities. The biological alterations underlying this pattern remain unknown.
Methods: Pangenomic analysis (n = 39), TP53 (n = 43) and PIK3CA (n = 41) sequencing in a series of IMPCs were
performed. A subset of cases was also analysed with whole-exome sequencing (n = 4) and RNA sequencing (n = 6).
Copy number variation profiles were compared with those of oestrogen receptors and grade-matched invasive ductal
carcinomas (IDCs) of no special type.
Results: Unsupervised analysis of genomic data distinguished two IMPC subsets: one (Sawtooth/8/16) exhibited a
significant increase in 16p gains (71%), and the other (Firestorm/Amplifier) was characterised by a high frequency of 8q
(35%), 17q (20% to 46%) and 20q (23% to 30%) amplifications and 17p loss (74%). TP53 mutations (10%) were more
frequently identified in the amplifier subset, and PIK3CA mutations (4%) were detected in both subsets. Compared to
IDC, IMPC exhibited specific loss of the 6q16-q22 region (45%), which is associated with downregulation of FOXO3 and
SEC63 gene expression. SEC63 and FOXO3 missense mutations were identified in one case each (2%). Whole-exome
sequencing combined with RNA sequencing of IMPC allowed us to identify somatic mutations in genes involved in
polarity, DNAH9 and FMN2 (8% and 2%, respectively) or ciliogenesis, BBS12 and BBS9 (2% each) or genes coding for
endoplasmic reticulum protein, HSP90B1 and SPTLC3 (2% each) and cytoskeleton, UBR4 and PTPN21 (2% each), regardless
of the genomic subset. The intracellular biological function of the mutated genes identified by gene ontology analysis
suggests a driving role in the clinicopathological characteristics of IMPC.
Conclusion: In our comprehensive molecular analysis of IMPC, we identified numerous genomic alterations without any
recurrent fusion genes. Recurrent somatic mutations of genes participating in cellular polarity and shape suggest that
they, together with other biological alterations (such as epigenetic modifications and stromal alterations), could
contribute to the morphological pattern of IMPC. Though none of the individual abnormalities demonstrated specificity
for IMPC, whether their combination in IMPC may have a cumulative effect that drives the abnormal polarity of IMPC
needs to be examined further with in vitro experiments.Introduction
Breast carcinomas encompass numerous morphologies,
phenotypes and molecular alterations [1-3]. Recent com-
prehensive genomic studies have focused on the most
common histological (that is, invasive ductal carcinoma
of no special type (IDC-NST) and lobular carcinoma) or* Correspondence: anne.salomon@curie.fr
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reproduction in any medium, provided the ormolecular (that is, luminal, triple-negative or ERBB2)
groups [4-7]. In the present study, we provide a compre-
hensive molecular characterisation of invasive micropa-
pillary carcinoma (IMPC), one of the special types of
invasive breast carcinoma. IMPC represents less than 2%
of all invasive breast cancers [2]. This entity is charac-
terised by proliferation of carcinomatous cells organised
in clusters, separated from the extracellular matrix by
an empty clear space with the cellular apical surfacetd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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is clearly visualised by epithelial membrane antigen
(EMA) or MUC1 staining [1] and is the hallmark of this
entity.
Up to 70% of patients with IMPC have peritumoural
lymphovascular invasion (LVI). This LVI rate is higher
than the rates usually observed in IDC-NST (20%).
Despite the aggressive phenotype, however, IMPC is as-
sociated with a prognosis similar to that of IDC-NST
and with the same axillary lymph node status [8-11].
Weigelt et al. [3] showed that IMPC are part of the
transcriptomic luminal spectrum of tumours, albeit
that this observation was based on the analysis of
only eight cases. Researchers in two previous genomic
studies based on small series of 16 and 10 cases, re-
spectively [12,13], identified specific genomic patterns
of IMPC, such as 8p losses, 8q gains and 17p and
16q losses in 50% to 100% of cases. These observa-
tions were confirmed by a recent study [14]. Another
study subsequently demonstrated that the majority of
IMPC cases were oestrogen receptor (ER)–positive
and associated with a high proliferation rate and
could therefore be considered luminal B tumours
[13]. Furthermore, Marchio et al. demonstrated the
existence of three different genomic patterns: “sim-
plex”, with segments of duplication and deletion of
entire chromosomes or chromosome arms; “sawtooth”,
with numerous low-level regions of gains or losses; and
“firestorm”, with numerous amplifications. In addition,
compared to ER- and grade-matched IDC-NST, some
genomic alterations were observed more predominantly
in IMPC, such as amplification on chromosomes 8p, 8q
and 17q.
Despite the results of these previous molecular
studies, the biological alterations leading to polarity
modifications of IMPC cells associated with high
rates of axillary lymph node and LVI have still to be
elucidated.
The present study, based on comprehensive genomic
analysis by TP53, PIK3CA, SEC63 and FOXO3 Sanger
sequencing, SNP6.0 and transcriptomic analyses of a
large series of IMPC and based on whole-exome and
RNA sequencing of a subset of cases, identified recur-
rent mutations in genes enriched in cell polarity, cilio-
genesis, cell shape and cytoskeleton organisation that




We retrospectively selected 77 cases of invasive
breast cancer (50 pure IMPC and 27 IDC-NST) on
the basis of the availability of both paraffin blocks
and frozen specimens from the Institut Curie (45IMPC and 27 IDC-NST) and Centre Georges Fran-
çois Leclerc (5 IMPC) tumour banks. The initial
treatment was surgery in all selected cases. These
cases were reviewed by three experienced breast pa-
thologists (AVS, PF and LA) and classified according
to the World Health Organization criteria [1]. IMPC
cases were confirmed on the basis of inside-out MUC1
staining (cancer antigen 15-3 (CA 15-3), monoclonal
antibody, clone DF3; AbCys, Paris, France) at the
inverted apical pole [15]. IDC-NSTs were selected as
being ER-positive and were grade-matched with IMPC
cases.
Whole-exome sequencing was performed for four
IMPC cases and their normal DNA (peritumoural),
and targeted sequencing validation was performed for
forty-seven IMPC cases with a MiSeq Gene & Small
Genome Sequencer (Illumina, San Diego, CA, USA).
Analysis using the Affymetrix Genome-Wide Human
SNP 6.0 Array (Affymetrix, Santa Clara, CA, USA) was
feasible for 39 IMPC cases, and whole-transcriptome
sequencing was performed for 6 IMPC cases. The
types of analyses and number of cases are listed in
the flowchart in Additional file 1: Figure S1. All ex-
periments were performed in accordance with French
Bioethics Law 2004-800 and the French National In-
stitute of Cancer Ethics Charter and with the approval
of the Institut Curie Institutional Review Board and
the ethics committees of our institution (“Comité de
Pilotage of the Groupe Sein”). The patients gave their
written informed consent for us to use their tumour
specimens for research. The data were analysed
anonymously.
Immunohistochemical analyses
Sections (4 μm thick) were cut from formalin-fixed,
paraffin-embedded tissues derived from whole tissue
sections from representative blocks for each case. These
sections were cut, dried, deparaffinised and rehydrated
according to standard procedures. All sections were sub-
jected to heat-induced antigen retrieval in citrate buffer
(pH 6.1). Antibodies against ERα (clone 6 F11, 1:200;
Novocastra, Milton Keynes, UK), ERBB2 (clone CB11,
1:1,000; Novocastra) and MUC1 (clone DF3, 1:100; Bio
SB, Goleta, CA, USA) were incubated for 1 hour at
room temperature. Staining for horseradish peroxidase
antimouse and antirabbit immunoglobulin G was de-
tected with the universal VECTASTAIN Elite ABC Kit
(Vector Laboratories, Burlingame, CA, USA) with diami-
nobenzidine (Dako A/S, Glostrup, Denmark) as chromo-
gen. Internal and external controls were included for each
antibody. The American Society of Clinical Oncology–
defined cutoffs were used to determine whether cases
were positive for ER (≥1%) or for ERBB2 (≥30%) by
complete and intense membranous staining [16,17].
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DNA and RNA extraction
DNA extraction and preparation for microarray experi-
ments of tumour DNA were performed by the Institut
Curie Biological Resource Center. Prior to DNA isola-
tion, a tissue section of tumour fragments was obtained
and then stained with haematoxylin and eosin to evalu-
ate tumour cellularity. All tumours analysed contained
more than 70% of tumour cells on the frozen tissue
section after manual microdissection of the frozen
specimen. DNA was extracted from frozen tumour
samples using a standard phenol/chloroform-based
procedure. The quality of DNA was assessed on agar-
ose gels. When a smear instead of a band was ob-
served, the sample was discarded. RNA extractions
were performed using a standard previously described
procedure [18].
Affymetrix Genome-Wide Human SNP 6.0 Array profiling
and analysis of genomic alterations
Single-nucleotide polymorphism (SNP) mapping assays
were performed according to the manufacturer’s proto-
col (Affymetrix). Briefly, 250 ng of genomic DNA were
digested with both Nsp and Sty restriction enzymes in
independent parallel reactions (Genome-Wide Human
SNP Nsp/Sty Assay Kit 6.0; Affymetrix), ligated to the
adaptors and amplified by PCR using a universal primer.
After purification of PCR products with SNP clean mag-
netic beads (Agencourt Bioscience, Beverly, MA, USA),
amplicons were quantified, fragmented, labelled and hybri-
dised to the Affymetrix Genome-Wide Human SNP 6.0
Array. Targets were prepared when 45 μg of amplified
DNA were available and when the targets’ size was situ-
ated between 250 and 2,000 bp, and then they were hybri-
dised according to the manufacturer’s recommendations.
After washing and staining, the arrays were scanned to
generate .cel software files for downstream analysis. Nor-
malisation was performed using a genotyping console
(GenomeWideSNP_6.hapmap270.na31.r1.a5.ref) provided
by Affymetrix (GTC3.0.1). The data discussed in the
present article have been deposited in the National Center
for Biotechnology Information (NCBI) Gene Expression
Omnibus [GEO:GSE37035] [19]. Genomic alterations were
evaluated according to the Genome Alteration Print (GAP)
methodology [20]. Copy number and allelic content profiles
were detected for each tumour based on the overall pattern
of alterations, as previously described and validated
[20]. The cutoffs for alteration events (gains, losses and
amplifications) were adapted according to the inferred
ploidy. For near-diploid tumours, the genomic region
with inferred copy numbers ≤1 or ≥3 and ≥6 were con-
sidered to be regions of loss, gain and amplification,respectively. For near-tetraploid tumours, the copy
number cutoffs used to define regions of loss, gain and
amplification were two, six and eight, respectively.
The minimal regions of amplification covering at
least 25 consecutive SNPs with the same copy num-
ber status were considered to be recurrent regions
when the frequency of alterations was higher than
20%. Tumour profiles were visualised using GAP
software (institut Curie)[20]. Partek GS software ver-
sion 6.5 build 6.10.1020 (Partek, St. Louis, MO, USA)
was used to generate hierarchical clustering of the
Affymetrix Genome-Wide Human SNP 6.0 Array
genomic data in the IMPC group. Ward’s method
with Euclidean distance was used to generate this
clustering.
The Cancer Genome Atlas breast cancer cohort
The mutational statuses of 358 breast cancers annotated
as a luminal subtype (PAM50 [21]) were extracted from
The Cancer Genome Atlas (TCGA) database [22]. The
frequency of mutations was calculated.
Quantitative RT-PCR
cDNA was generated using a reverse transcriptase kit
(High Capacity cDNA Reverse Transcription Kit, Applied
Biosystems, Foster City, CA, USA) from 1 μg of total
RNA. Assays-on-Demand for assessing expression level
of SEC63, FOXO3 as well as the control TATA-binding
protein (TBP) genes were obtained from Applied Bio-
systems. Quantitative RT-PCR was carried out in an
ABI PRISM 7500 Real-Time Thermal Cycler using Taq-
Man Master Mix (Applied Biosystems).
Classical Sanger sequencing
Classical Sanger sequences were performed for the follow-
ing genes: TP53 (exons 4 to 10; n = 45 cases), PIK3CA
(exons 8, 10 and 21; n = 39 cases), SEC63 (exons 1 to 21;
n = 43 cases) and FOXO3 (exons 2 to 4; n = 51 cases).
Each PCR was performed on 30 ng of tumour DNA
(TP53 and PIK3CA) or cDNA (SEC63 and FOXO3). These
genes were PCR-amplified and bidirectionally sequenced
using BigDye Terminator chemistry (Applied Biosystems)
with an ABI PRISM 3700 DNA Analyzer. The primer
sequences are available in Additional file 2: Table S6.
The functional impact of change in amino acids was de-
termined on the basis of scoring using the PolyPhen-2
tool [23].
Whole-exome sequencing
Whole-exome sequencing was performed using the Sure-
Select Human All Exon 50 Mb Kit (Agilent Technologies)
and the SOLiD™ experimental tracking software V4 system
(Applied Biosystems). Coloured space paired-end reads
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Browser hg19 genome (NCBI build 37.1) using bfast +
bwa v0.7.0a [24]. Reads with mapping quality <20 and
reads which were marked as duplicates by Picard v1.65
were excluded from further analysis.
Putative somatic single-nucleotide variants (SNVs) were
subsequently called in exome data using SAMtools mpi-
leup (v0.1.18 (r982:295)) [25] and VarScan v2.2.11 [26].
False-positive SNVs were excluded using the following
thresholds: Fisher’s exact test P < 0.05, coverage ≥10×,
Phred base quality score ≥20, minimum variant allele fre-
quency ≥20% and high-quality reads supporting variants
allele ≥4.
For prioritisation, we omitted (1) known variants
from the 1000 Genomes Project and dbSNP Coriell
Cell Repository ID V137 and (2) selected missense
variants with functional impact scores >0.5 and Gen-
omic Evolutionary Rate Profiling (GERP) scores >3.0.
We used the SeattleSeq Annotation 137 server (v7.05,
June 2012) [27]. A set of potentially deleterious som-
atic missense SNVs was validated by classical Sanger
sequencing. The validated missense variants were
screened in an independent series (n = 47) by targeted
sequencing on the Illumina MiSeq platform from
IntegraGen (Evry, France). The Reactome FI Cytos-
cape Plugin (National Institute of General Medical
Sciences, US National Institutes of Health, Bethesda,
MD, USA) was used to determine the observed inter-
actions between the mutated genes identified [28]. For
whole-exome and MiSeq sequencing, the average tar-
geted bases covered at 25× were 65% and 68%,
respectively.
To determine the functional impact of mutations
identified in exome sequencing, PolyPhen-2 (v2.2.2,
March 2012) and GERP scores were assessed [23,29].
Accumulative scores were defined on the basis of differ-
ent predictor tools, including MutationTaster, Condel
and MutationAssessor. The thresholds for these com-
bined scores were as follows: for PolyPhen-2, 1 = probably
damaging with probable impact on protein structure and
function and 0 = benign with no impact on protein struc-
ture and function; for GERP, <3 = benign, 3 to 5 = possibly
damaging and >5 = probably damaging.
RNA sequencing
Library preparation and paired-end (2 × 100 bp) RNA
sequencing were performed by IntegraGen using a Tru-
Seq RNA Sample Prep Kit and a HiSeq 2000 platform
(both from Illumina), respectively. On average, 130 mil-
lion reads were obtained for each sample. RNA sequen-
cing raw reads were mapped using TopHat v2.0.6 [30]
and bowtie v2.0.4 against the UCSC Genome Browser
hg19 genome (NCBI build 37.1). SNV and transcriptome
quantitative analysis were performed using SAMtoolsv0.1.8 and Cufflinks v2.0.2 [31], respectively. Expression
level of validated mutations was determined using RNA
sequencing data. Gene fusion analyses were performed
using two known tools TopHat-Fusion v2.0.4 and deFuse
v0.6 (for more detail please refer to Additional file 3:
Table S8) [32-34]. Fusion’s validation was performed
using RT-PCR (primers listed in Additional file 4:
Table S9).
Gene expression analysis
The DNA microarray used in this study was the GeneChip
Human Genome U133 Plus 2.0 Array (Affymetrix), con-
taining 54,613 probe sets. Microarray data were simultan-
eously normalised using the GC robust multiarray average
package 1.2 in the R environment (R Development Core
Team). In this article, expression data are used to deter-
mine correlations between the genomic status of genes
localised within the chromosome 6q region of minimal
deletion and their level of expression by comparing the
log2 expression signal and the DNA copy number signals
using Pearson’s correlation test. A correlation between ex-
pression levels with respect to DNA copy number was
considered significant when the R-value was >0.4 and the
P-value was ≤0.05.
Results
IMPC tumours were predominantly pT1N1 ER-positive
with high rates of ERBB2 overexpression for T1 tumours
The aim of this exploratory study was to decipher gen-
omic alterations related to the specific morphology of
IMPC tumours, that is, the inverted polarity of cells,
organised in clusters separated from the extracellular
matrix by a clear space (Figures 1A and 1B). IMPC tu-
mours have previously been identified as luminal carcin-
omas. The 39 IMPC tumours subsequently analysed by
Affymetrix Genome-Wide Human SNP 6.0 Array were
therefore compared to 27 ER-positive and grade-matched
IDC-NSTs. All clinicopathological data are provided in
Additional file 5: Table S1.
On the basis of the PAM50 gene list [35], the transcrip-
tomic analysis of IMPC tumours showed that they were
either luminal A (18 of 34 cases) or luminal B (16 of 34
cases) (Additional file 6: Figure S2).
The median ages of the IMPC and IDC-NST patients
were 62 and 60 years, respectively, and all patients were
treated and followed at the Institut Curie between 1990
and 2010. The majority of IMPC tumours were T1
(72%), grade 2 (51%) and ER-positive (100%), and ERBB2
overexpression was observed in 26% of cases.
IMPC tumours harboured 17q gain/amplification
associated with 6q deletion
The copy number and allelic status of each altered re-
gion in the tumour genome were determined in order to
Figure 1 Phenotypic and genomic characterisation of invasive micropapillary carcinoma. (A) and (B) Histological samples of an invasive
micropapillary carcinoma (IMPC) of the breast composed of cell clusters surrounded by empty spaces and displaying an inside-out growth pattern, as
highlighted by MUC1 staining. (C) Frequency plots of gains and losses are displayed from chromosome 1pter on the left to chromosome Xq on the
right. Alternating grey and white bands indicate chromosome boundaries. Dashed blue line represent 40% frequencies, − for losses and + for gains,
respectively. ER, Oestrogen receptor; IDC-NST, Invasive ductal carcinoma of no special type.
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tumour sample. The number of breakpoints (defined as
a change in copy number or allelic status within a
chromosome) was evaluated for each tumour. The me-
dian numbers of breakpoints in IMPC tumours and in
ER-positive and grade-matched IDC-NSTs were almost
identical (65 for IMPC tumours and 79 for IDC-NSTs).
Frequencies of gains and losses are shown in Figure 1C.
Recurrent amplifications (observed in more than 40% of
cases) were identified on chromosomes 8q and 17q, as
listed in detail in Table 1. The three most frequent re-
gions of amplification observed in IMPCs were 8q22.1,
8q23.3-q24.23 and 17q22-q23.3, encompassing RAD54B,
CCNE2 and TP53INP1 (21% vs 5% in IDC-NSTs), MYC
(21% vs 14% in IDC-NSTs) and BCAS3, PPM1D, TLK2,
TBX2 and TANC2 (22% vs 7%), respectively. IMPC cases
also presented amplifications in the ERBB2 region (22%
vs 24% in IDC-NSTs).
As expected, some of the most frequent recurrent
changes (observed in at least 40% of cases) were thosecommonly found in luminal B breast cancers, with gains
of 8q being associated with losses of 8p, 16q, 17p and
22q [36]. However, compared to IDC-NSTs, IMPCs spe-
cifically harboured more gains of chromosome 17q22-
q24.3 (47% vs 25%) and more losses of chromosome
6q16.3-q22.31 (45% vs 20%) (Table 1). This chromosome
6q loss was associated with loss of heterozygosity
(Table 1 and Figure 2B).
Identification of two different genomic subsets of
invasive micropapillary carcinomas
Heterogeneous copy number profiles with a high fre-
quency of recurrent regions of amplification and fre-
quent combinations of recurrent alterations (such as
chromosome 8p loss, 8q gain, 16q loss, 17q and/or 20q
amplifications) observed in the IMPC group prompted
us to search for genomic subsets. By unsupervised clus-
tering analysis of IMPC data derived from the Affyme-
trix Genome-Wide Human SNP 6.0 Array, we identified
two major clusters among IMPCs (Figure 2A). The first
Table 1 Frequencies of regions of gains, losses and amplifications in invasive micropapillary carcinomas and in
oestrogen receptor–positive and grade-matched invasive ductal carcinomas of no special typea
SNP start SNP end Chr Cytoband IMPCs (%) IDC-NSTs (%) Genes of interest
Common regions
Gains
36948617 146292734 8 p11.23-q24.3 60 45
Losses
113565 35436036 8 p23.3-p12 63 63
46534977 90163275 16 q11.2-q24.3 55b 54
6689 18896297 17 p13.3-p11.2 46 43b
16055171 51219006 22 q11.1-q13.33 52 40
Specific regions
Gains
197811282 249198692 1 q31.3-q44 23 48
52579874 67308196 17 q22-q24.3 47 25
33435161 62648208 20 q13.12-q13.33 17 44
Losses
101380020 125365648 6 q16.3-q22.31 45b 20
705598 13611533 18 p11.32-p11.21 15 42
28175177 35313501 18 q12.1-q12.2 24 40
Amplifications
37097563 38618768 8 p11.23-p11.22 13 26 FGFR1, PPAPDC1B, WHSC1L1
94967717 97023919 8 q22.1 21 5 RAD54B, CCNE2, TP53INP1
115849871 138121678 8 q23.3-q24.23 21 14 MYC
69073647 70229171 11 q13.3-q25 7 22 CCND1, ORAOV1, FGF19, FGF4, FGF3
37298761 38225021 17 q12-q21.1 22 24 STARD3, ERBB2, GRB7
57159990 62354992 17 q22-q23.3 22 7 BCAS3, TBX2, TLK2, TANC2, PPM1D
50695849 52586281 20 q13.2 15 26 ZNF217, BCAS1
aChr, Chromosome; IDC-NST: invasive carcinoma of no special type; IMPC, Invasive micropapillary carcinoma; SNP, Single-nucleotide polymorphism. Recurrent
gains, losses or amplifications observed in more than 20% of cases after exclusion of genomic variants according to the Database of Genomic Variants (http://dgv.
tcag.ca/dgv/app/home). SNP start and SNP end refer to SNP positions corresponding to the boundaries of gains, losses or amplifications. Genomic positions are
provided according to human genome 19 (hg19) references in base pairs. bExistence of a homozygous deletion is observed in one case among IMPCs and IDC-NSTs
studied. The lower part of the table lists the specific regions of gains, losses and amplifications that were statistically different between IMPCs and IDC-NSTs
with P < 0.05 by Fisher’s exact test.
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gions of amplification located on chromosomes 8q, 17q
and 20q, with frequencies ranging from 20% to 46%,
hereinafter called the “Firestorm/Amplifier” subset [37].
The second cluster was composed of 16 cases (41%) har-
bouring rare regions of amplification, but whole-arm
copy number alterations such as 8p−/8q+/16p−/16q+,
hereinafter called the “Sawtooth/8/16” subset [37].
Different gains and losses distinguished “Firestorm/
Amplifier” from “Sawtooth/8/16” subsets of IMPCs
(detailed in Figure 2B and Additional file 7: Table S2).
Differences in genomic alterations between each of these
two IMPC subsets and IDC-NSTs were then identified
(presented in Additional file 8: Table S3 and Additional
file 9: Table S4). In contrast to their genomic differences,the two IMPC subsets harboured identical rates of
grade 3 LVI- and ER-positive cases and the same clin-
ical stage distribution (size and N+ number) (Additional
file 10: Table S5).
SEC63 and FOXO3 genes, localised in 6q minimal region
of deletion observed in both genomic groups of IMPCs,
downregulation and mutation
We delineated a 1.59-Mb minimal region of 6q deletion,
observed in 45% of all IMPC cases. This region was ob-
served more frequently in IMPCs than in all IDC-NSTs
(Figure 2B) and luminal B IDC-NSTs (Additional file 11:
Table S7 and Additional file 12: Figure S3). This deletion
was further associated with a loss of heterozygosity
specific to IMPCs. This region encompassed nine
Figure 2 Identification of two invasive macropapillary carcinoma genomic subgroups. (A) Unsupervised hierarchical clustering of
39 (IMPC) tumours using Affymetrix Genome-Wide Human SNP 6.0 Array data with Partek software. Each column represents a different
tumour, and each row represents single-nucleotide polymorphism (SNP) status (green for losses, red for gains and/or amplifications).
Colour coding in lines above the dendrogram: black in top row = Oestrogen receptor–positive (ER+); pink = ERBB2 amplification; brown
= ERBB2 overexpression; green = Lymph node metastasis (N+); blue = Lymphovascular invasion–positive (LVI+); pale grey = grade 1;
dark grey = grade 2; black in bottom row = grade 3. (B) Frequencies of genome copy number gains and losses plotted as a function
of genome location in “Sawtooth/8/16” IMPC (upper panel) and “Firestorm/Amplifier” IMPC (middle panel). Gains and losses are
displayed above or below the blue line, respectively, from chromosome 1pter on the left to chromosome Xq on the right. Alternating
grey and white bands indicate chromosome boundaries. The regions exhibiting significantly more frequent gains or losses between
“Sawtooth/8/16” IMPC and “Firestorm/Amplifier” IMPC are indicated above and below the frequency plots, respectively. Frequency of
loss of heterozygosity (LOH) of chromosome 6q assessed on the basis of Affymetrix Genome-Wide Human SNP 6.0 Array profiles
observed in the tumours presenting a deletion of the chromosome 6 long arm. The minimal region of deletion is highlighted. cent,
Centromere; tel, Telomere. (C) Real-time PCR results of relative expression of SEC63 and FOXO3 genes in samples of IMPC without
(n = 6; dark-grey diamond) and with (n = 9; light-grey diamond) chromosome 6q deletion and in invasive ductal carcinoma of no
special type (IDC-NST) (n = 11; circle) (in red: median relative value/Tata Binding Protein). w/o, without; w, with. *P ≤ 0.05, **P ≤ 0.001.
(D) Summary of the common and distinct genomic alterations between IMPC genomic subgroups and ER+ IDC-NSTs.
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(GRCh37/hg19, February 2009). Two of the nine genes,
SEC63 and FOXO3, encompassed by the commonregion of deletion were underexpressed in IMPC cases
(P ≤ 0.05 by Welch test, fold change ≥1.5, real-time quan-
titative RT-PCR) (Figure 2C) and were consequently
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Additional file 7: Table S6. One of the thirty-eight cases
(IMPC 10; 2% of cases) presented three FOXO3 mis-
sense mutations (Figure 3 and Table 2). One of forty-Figure 3 Mutation landscape in invasive micropapillary carcinoma ac
pathway interactions between the 23 mutated genes. (A) Distribution
whole-exome sequencing, targeted MiSeq sequencing and classical Sanger se
of significant mutations across sequenced samples with color-coding accordi
Human SNP 6.0 Array analysis. Yellow = neutral copy number; green = deletio
chromosome 6q allelic status (light green = loss of heterozygosity; dark green
diploid), invasive micropapillary carcinoma (IMPC) genomic group (red = “Fire
status (dark blue = positive), ERBB2 overexpression (orange = positive 3+), grad
axillary lymph node status (dark = N+). Chr, chromosome; ND, Not determ
and UCSC Genome Browser. (B) Interactions and pathways between the
[38]. In this diagram, the functional interaction (FI) network connections a
in perpendicular line for inhibition, solid lines for FIs extracted from comp
defined FIs.one cases, IMPC 31, presented a SEC63 missense muta-
tion (Figure 3 and Table 2). On the basis of its
PolyPhen-2 score of 1, this mutation was considered
deleterious.cording to grade, genomic subgroup and phenotype and
of validated somatic mutations among the 50 cases as determined by
quencing (TP53, PIK3CA, SEC63 and FOXO3). Central heatmap: distribution
ng to the allelic genomic status determined by Affymetrix Genome-Wide
n, dark pink = gain. Upper chart color-coding from top to bottom:
= deletion), tumour ploidy (dark purple = tetraploid; light purple =
storm/Amplifier”; green = “Sawtooth/8/16”), oestrogen receptor (ER)
e (light grey = grade 1; intermediate grey = grade 2; dark grey = grade 3),
ined. Function is defined according to the Gene Ontology database
23 mutated genes in IMPCs deduced from the Reactome algorithm
re symbolised by arrows for activating/catalysing, solid lines ending
lexes or inputs, dashed lines for predicted FIs and dotted lines for
Table 2 Mutations in invasive micropapillary carcinomas
Gene Cases, n (%) Chr Mutation WH seq MiSeq Sanger seq Effect of the mutation Type of mutation PolyPhen-2 score GERP score RNA-seq expression
TP53 5 (10) 17 GAA>CAA/p.E286Q X NA X Missense Transversion 1.00 Yes
ATG>ACG/p.M246T X NA X Missense Transition 1.00 Yes
GAG>AAG/p.E68K NA NA X Missense Transition 0.09 ND
TAC>TGC/p.Y234C NA NA X Missense Transition 0.97 ND
c.742_743insA NA NA X Frame shift Ins/del 5.91 ND
DNAH9 4 (8) 17 A>G X X X Splice intron Transition 4.05 No coverage
CGG>CAG/p.R2605Q X X X Missense Transition 1.00 No coverage
ATG>ATA/p.M3430I NA X X Missense Transition 0.00 ND
CAG>TAG/p.Q3082* NA X X Nonsense Transition 4.05 ND
FBXO38 2 (4) 5 TAT>TGT/p.Y1058C X X X Missense Transition 1.00 Yes
GAA>CAA/p.E20Q NA X X Missense Transversion 0.96 ND
THSD4 2 (4) 15 GAG>AAG/p.E476K X X X Missense Transition 1.00 Yes
GAG>AAG/p.E652K NA X X Missense Transition 0.96 ND
TRMT5 2 (4) 14 TTT>CTT/p.F303L X X X Missense Transition 0.04 Yes
GAG>CAG/p.E152Q NA X X Missense Transversion 0.03 ND
PIK3CA 2 (4) 3 CTC>GTC/p.L540V NA NA X Missense Transversion 0.99 ND
CAG>CCG/p.Q546P NA NA X Missense Transversion 1.00 ND
FOXO3 1 (2) 6 GCA>ACA/p.A267T NA NA X Missense Transition 0.97 ND
CCT>TCT/p.P292S NA NA X Missense Transition 0.34 ND
TTG>GTG/p.L528V NA NA X Missense Transversion 0.03 ND
BBS12 1 (2) 4 CGC>TGC/p.R674C X X X Missense Transition 1.00 Yes
BBS9 1 (2) 7 CCA>TCA/p.P77S X X X Missense Transition 1.00 No coverage
CASP8AP2 1 (2) 6 GAT>AAT/p.D1420N X X X Missense Transition 1.00 No coverage
EIF2B5 1 (2) 3 GCA>ACA/p.A406T X * X Missense Transition 0.05 Yes
FMN2 1 (2) 1 GCT>CCT/p.A659P X * * Missense Transversion 0.74 No coverage
HSP90B1 1 (2) 12 ACG>ATG/p.T468M X X Missense Transition 0.98 Yes
IKBKE 1 (2) 1 GAC>TAC/p.D571Y X * X Missense Transversion 0.68 Yes
PCF11 1 (2) 11 AAT>AGT/p.N167S X X X Missense Transition 0.02 Yes
PLCL1 1 (2) 2 AAG>AAT/p.K279N X X X Missense Transversion 0.98 No coverage
PTPN21 1 (2) 14 CGA>CTA/p.R864L X X X Missense Transversion 1.00 Yes
SEC63 1 (2) 6 CGC>TGC/p.R217C NA X X Missense Transition 1.00 ND
SPTLC3 1 (2) 20 G>A X X X Splice intron Transition 5.91 No coverage













Table 2 Mutations in invasive micropapillary carcinomas (Continued)
SYNRG 1 (2) 17 ATG>ATA/pM970I X * X Missense Transition 0.45 Yes
UBR4 1 (2) 1 AAC>AAA/p.N3400K X X X Missense Transversion 0.98 Yes
ZFYVE26 1 (2) 14 CAA>CCA/p.Q1582P X X X Missense Transversion 0.00 Yes
a%, Percentage of mutated cases out of the sequenced cases; *Assessed but not identified with the technique; Chr, Chromosome; GERP, Genomic Evolutionary Rate Profiling; IMPC, Invasive micropapillary carcinoma;
NA, Not assessed with this technique; ND, Not determined (that is, no RNA sequence available for that sample); No coverage, Absence of aligned reads at the corresponding genomic position; WH seq, Whole-exome
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sequencing analysis
We conducted whole-exome sequencing analyses of four
IMPC cases (one “Sawtooth/8/16” and three “Firestorm/
Amplifier”), followed by targeted sequencing analyses
(MiSeq) of forty-seven IMPC cases. Twenty-nine tumour-
specific, nonsynonymous variants were identified, twenty-
two of which were validated by classical Sanger sequencing.
Altogether, 36 nonsynonymous variants were identified
by classical Sanger, whole-exome and targeted (MiSeq)
sequencing. These nonsynonymous variants were located
in 23 different genes and observed in 14 of the 47 IMPC
samples (30%). One-third of the mutated samples har-
boured more than one nonsynonymous variant. These
nonsynonymous variants corresponded to missense mu-
tations in 89% (32 of 36) of cases and transition in 22 of
36 cases (61%). They were considered deleterious ac-
cording to PolyPhen-2 score (higher than 0.5) and GERP
score (higher than 4) in 26 (72%) of 36 cases (Table 2).
RNA sequencing identified seven putative fusion genes.
Six of them were further validated (Figure 4): RERE-
ACTNA4 t(1;19)(p36.23;q13.2), HEATR7-RSPRY1 t(8;16)
(q24.3;q13), ZNF8-GIP t(19;17)(q13.43;q21.32), ZNF256-
SKA2 t(19;17)(q13.43;q22), DUS1L-B4GALNT2 t(17;17)
(q25.3;q21.32) and CHD6-GATA5 t(20;20)(q12;q13.33).
All but one of the fusions were private events andFigure 4 RNA sequencing identification and validation of the six fusio
representations of the fusions between gene 1 and gene 2 are displayed with
scheme, the underlined codon is a stop codon. RT-PCR detection of fusion ge
panel for each fusion. The numbers of split and spanning reads, together with
Table S8. Primer sequences used for RT-PCR validation are provided in Additioobserved in one of the thirty-three cases analysed. The
ZNF8-GIP fusion was observed in two of thirty-three
cases. In addition, two IMPC samples demonstrated
several fusion genes (two and three fusion genes per
sample). These cases were also associated with point
mutations.
Invasive micropapillary carcinomas harboured mutations
in genes involved in polarity, ciliogenesis and cell shape
The three most frequently mutated genes in our series
of IMPCs were TP53 (10%), DNAH9 (8%) and PIK3CA
(4%) (Figure 3A). Among the cases with only TP53 mu-
tations, two also had mutations in genes involved in
ciliogenesis (DNAH9, BBS12 and BBS9) or in cytoskel-
eton organisation (UBR4 and PTPN21). Among the eight
cases without TP53 or PIK3CA mutations, three demon-
strated multiple mutations (two to six mutations per
case). These multiple mutations are located in genes
coding for proteins that play a key role in cell polarity
(FMN2 and SEC63 (one case (2%) each) or in biological
processes necessary for cell polarity or cell shape, such
as ciliogenesis (DNAH9 (two cases (4%), or cytoskeleton
(ZFYVE26 (one case (2%)). Interactions between the 23
mutated genes and existing signalling pathways were in-
vestigated with the Reactome algorithm and are shown
in Figure 3B. Fifteen (68%) of twenty-two of thens found in invasive micropapillary carcinoma. Schematic
the precise sequence of the breakpoint region. In the ZNF8_GIP fusion
nes in tumour (T) and constitutional (C) RNAs are shown on the right
the genomic strands of the fused genes, are given in Additional file 3:
nal file 4: Table S9. chr, Chromosome; UTR, Untranslated region.
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http://breast-cancer-research.com/content/16/3/R46validated mutations were found to be expressed at the
RNA level, which was strongly correlated with Affymetrix
Genome-Wide Human SNP 6.0 Array gene expression
levels (R = 0.86) found in the RNA sequencing data.
Discussion
In this study, we show that IMPC (1) were luminal and
predominantly pT1N1 with high rates of ERBB2 overex-
pression, (2) were associated with 17q gain/amplification
and 6q deletion, (3) encompassed two different genomic
subsets (Firestorm/Amplifier or Sawtooth/8/16), (4) har-
boured SEC63 and FOXO3 gene downregulation and
mutation (2% of cases each) and (5) were localised in the
6q minimal region of deletion. We also describe the gen-
omic landscape of pure micropapillary carcinomas by
using tools that enabled us to gain insight into the muta-
tions in genes participating in polarity, ciliogenesis, cell
shape and cytoskeleton organisation and private trans-
location at high resolution.
IMPCs presented with complex genomic profiles and nu-
merous gains, losses or high-level amplifications as well as
numerous breakpoints, and, in line with their luminal
phenotype, demonstrated a genomic profile that shared
similarities with that of ER+N+LVI+ IDC-NSTs with regard
to 8q gains and 8p, 16q and 22q losses. Some of these alter-
ations have previously been reported to be preferentially as-
sociated with luminal B group carcinomas, such as 8q
gains, 8p and 16q losses [14,36,39]. However, the high reso-
lution of the present analysis allowed us to identify differ-
ences between the two groups, in particular chromosome
17q22-q24.3 gains and 6q16.3-q22.31 losses in IMPCs.
In the present study, we show not only that these 6q
losses exist, confirming a previous report of chromo-
some 6q losses by Marchio et al. [13], but also show that
they were associated with allelic losses in this region.
We also found a correlation between genomic status and
transcriptomic expression level of the genes located
within this 6q region. Two of these genes, SEC63 and
FOXO3, were downregulated. We identified a missense
mutation in SEC63 and three mutations at different po-
sitions in FOXO3 (Table 2). Both the SEC63 and FOXO3
proteins have recently been identified as participating in
cell polarity control. SEC63 encodes for an endoplasmic
reticulum protein involved in the early stage of multi-
spanning membrane protein synthesis [40] and has been
found to be mutated in polycystic liver and kidney dis-
eases [41]. SEC63 protein also participates in quality
control and trafficking of proteins necessary for ciliogen-
esis, and therefore for epithelial cell polarity [42].
FOXO3 is known to regulate LKB1 gene transcription,
and the LKB1 protein plays a key role in cell planar po-
larity during cell division [43]. FOXO3 downregulation
has also recently been reported in high-grade serous
ovarian carcinoma [44].The IMPCs we studied had amplification rates of 20%,
considered to be high for such early tumours (stage T1).
One of the most frequently recurrent regions of amplifi-
cation observed in IMPCs was located on chromosome
17q22-q23.3. Notably, this region is the hallmark of the
cluster 1 of tumours of the METABRIC classification
[7,45] and encompasses druggable genes belonging to
the kinase family, such as TLK2 and the phosphatase
PPM1D. A the second frequently amplified recurrent re-
gion was the ERBB2 region, which was amplified in 22%
of cases, a higher rate than that observed in other T1
and small T2 IDCs [46,47].
Two of the most frequent regions of amplification in
the IDC-NST control group were located on chromo-
some 8p and on 11q13.3, which that encompass the
FGFR1 and PPAPDC1B genes [48] and the CCND1 gene,
respectively. The combination of the CCND1 11q and
8p regions of amplification has previously been reported
to be a characteristic of luminal carcinomas [49,50]. The
low frequency of amplification of these regions in IMPCs
is another genomic difference between luminal IDC-
NSTs and IMPCs.
Not surprisingly, TP53 and PIK3CA were among the
three most recurrent mutated genes in this series of
IMPCs. Although TP53 mutation rates were similar to
those reported in ER-positive breast carcinomas [7], it is
noteworthy that PIK3CA mutations were observed less
frequently in IMPCs than in other ER+ histological sub-
groups [14,51]. Notably, the number of PIK3CA muta-
tions observed in our series of pure IMPCs is much
lower than a rate reported recently (four of twenty pure
and mixed invasive micropapillary carcinomas) [52].
DNAH gene family mutations were recently identified
in triple-negative breast carcinomas, albeit at a very low
frequency (3%) [53]. In our present study of a special
type of breast cancer, we identified recurrent mutations
of the DNAH9 gene (8% of the cases) by whole-exome
sequencing analysis, a rate higher than that reported for
luminal IDCs in the TCGA analyses (3%). Dynein pro-
teins are necessary for correct apical and apicobasal lo-
calisation of the CRUMBS [54] and PAR3 [55] proteins.
Recurrent DNAH9 mutations in IMPC, characterised by
a polarity defect, may suggest a causative role of these
mutations in the IMPC pattern of growth that remains
to be demonstrated in vitro.
FMN2, a formin-like 2 gene, and the BBS9 and BBS12
genes also harboured mutations, although they were not
recurrent. These genes are involved in cell polarity, or-
ganisation and motility [56] or ciliogenesis [57]. We
noted that the BBS9 and BBS12 genes were not found to
be mutated in the TCGA luminal series. Interestingly, in
our particular series, these mutations are always associ-
ated with multiple other mutations (from four to five)
and located in genes coding for proteins that play a role
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and PTPN21).
These genes have also been identified to be mutated in
triple-negative breast carcinomas [4], which raises the
hypothesis of their role in tumour cell invasion and mo-
tility enhancement in triple-negative tumours or IMPCs.
All of these observations have to be confirmed with the
sequence of a larger number of IMPC cases at a higher
depth. The clinical impact of our results is not yet
straightforward. However, better knowledge of polarity
disorganisation in breast carcinomas and its role in
tumour progression could lead to new therapeutic strat-
egies if confirmed in a larger series. In agreement with
the findings of Natrajan et al. [14], we observed that
IMPCs are not associated with recurrent fusion genes.
Conclusion
In our comprehensive genomic analysis of IMPCs of the
breast, we identified numerous genomic alterations and
somatic mutations, but no recurrent fusion gene. We
demonstrate that IMPC is associated with a specific gen-
omic profile compared to ER+LVI+N+ IDC-NSTs, con-
sisting of gains of 17q, high rates of 17q22-23.3 and 17q12
ERBB2 amplifications and losses of 6q heterozygosity. The
presence of the SEC63 and FOXO3 genes located in this
6q loss of heterozygosity associated with deleterious som-
atic mutations suggests that they could play a role in the
abnormal polarity of IMPC cells. Considered together, the
mutation spectrum observed in IMPCs shows that, in
addition to TP53 and PIK3CA mutations, some IMPCs
harboured mutations in particular in genes involved in
ciliogenesis, polarity maintenance and cell shape (often
several such mutations per case). However, not all the
cases harboured mutations in these biological processes,
suggesting that other biological alterations (for example,
epigenetic modifications, stromal alterations) could con-
tribute to the morphologically specific pattern of IMPCs,
knowing that this hypothesis should be further supported
by in vitro experiments.
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